{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:48Z","timestamp":1792788768112,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PerkinElmer"},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 DK067859"],"award-info":[{"award-number":["R01 DK067859"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder caused by deficiency in arylsulfatase A activity, leading to accumulation of sulfatide substrates. Diagnostic and monitoring procedures include demonstration of reduced arylsulfatase A activity in peripheral blood leukocytes or detection of sulfatides in urine. However, the development of a screening test is challenging because of instability of the enzyme in dried blood spots (DBS), the widespread occurrence of pseudodeficiency alleles, and the lack of available urine samples from newborn screening programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We measured individual sulfatide profiles in DBS and dried urine spots (DUS) from MLD patients with LC-MS\/MS to identify markers with the discriminatory power to differentiate affected individuals from controls. We also developed a method for converting all sulfatide molecular species into a single species, allowing quantification in positive-ion mode upon derivatization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In DBS from MLD patients, we found up to 23.2-fold and 5.1-fold differences in total sulfatide concentrations for early- and late-onset MLD, respectively, compared with controls and pseudodeficiencies. Corresponding DUS revealed up to 164-fold and 78-fold differences for early- and late-onset MLD patient samples compared with controls. The use of sulfatides converted to a single species simplified the analysis and increased detection sensitivity in positive-ion mode, providing a second option for sulfatide analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>This study of sulfatides in DBS and DUS suggests the feasibility of the mass spectrometry method for newborn screening of MLD and sets the stage for a larger-scale newborn screening pilot study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1373\/clinchem.2015.245159","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T12:38:30Z","timestamp":1451479110000},"page":"279-286","source":"Crossref","is-referenced-by-count":73,"title":["Sulfatide Analysis by Mass Spectrometry for Screening of Metachromatic Leukodystrophy in Dried Blood and Urine Samples"],"prefix":"10.1093","volume":"62","author":[{"given":"Zdenek","family":"Spacil","sequence":"first","affiliation":[{"name":"Department of Chemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Babu Kumar","sequence":"first","affiliation":[{"name":"Department of Chemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Chieh","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Chemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Auray-Blais","sequence":"first","affiliation":[{"name":"Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, and Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Stark","sequence":"first","affiliation":[{"name":"National Referral Laboratory, Genetics and Molecular Pathology, South Australia Pathology, Women's and Children's Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teryn R","family":"Suhr","sequence":"first","affiliation":[{"name":"MLD Foundation, West Linn, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Ronald","family":"Scott","sequence":"first","affiliation":[{"name":"Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantisek","family":"Turecek","sequence":"first","affiliation":[{"name":"Department of Chemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Gelb","sequence":"first","affiliation":[{"name":"Department of Chemistry"},{"name":"Department of Biochemistry, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,1,1]]},"reference":[{"key":"2020022605325823700_B1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0006-291X(83)91815-6","article-title":"Pseudo arylsulfatase A deficiency: evidence for a structurally altered enzyme","volume":"112","author":"Fluharty","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"key":"2020022605325823700_B2","first-page":"1924","article-title":"Diagnosis of metachromatic leukodystrophy by immune quantification of arylsulphatase A protein and activity in dried blood spots","volume":"54","author":"Tan MAF","year":"2008","journal-title":"Clin Chem"},{"key":"2020022605325823700_B3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0387-7604(85)80010-3","article-title":"Analysis of fatty acids and sphingosines from urinary sulfatides in a patient with metachromatic leukodystrophy by gas chromatography-mass spectrometry","volume":"7","author":"Nishio","year":"1985","journal-title":"Brain Dev"},{"key":"2020022605325823700_B4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/clinchem\/42.2.232","article-title":"Urine sulfatides and the diagnosis of metachromatic leukodystrophy","volume":"42","author":"Natowicz","year":"1996","journal-title":"Clin Chem"},{"key":"2020022605325823700_B5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1006\/mgme.2001.3165","article-title":"Characterization of urinary sulfatides in metachromatic leukodystrophy using electrospray ionization-tandem mass spectrometry","volume":"73","author":"Whitfield","year":"2001","journal-title":"Mol Genet Metab"},{"key":"2020022605325823700_B6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10719-007-9067-7","article-title":"Synthetic sulfogalactosylceramide (sulfatide) and its use for the mass spectrometric quantitative urinary determination in metachromatic leukodystrophies","volume":"25","author":"Cui","year":"2008","journal-title":"Glycoconj J"},{"key":"2020022605325823700_B7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cca.2013.06.027","article-title":"Direct tandem mass spectrometric profiling of sulfatides in dry urinary samples for screening of metachromatic leukodystrophy","volume":"425","author":"Kucha\u00f8","year":"2013","journal-title":"Clin Chim Acta"},{"key":"2020022605325823700_B8","first-page":"39","article-title":"Quantification of sulfatides in dried blood and urine spots from metachromatic leukodystrophy patients by liquid chromatography\/electrospray tandem mass spectrometry","volume":"433C","author":"Barcenas","year":"2013","journal-title":"Clin Chim Acta"},{"key":"2020022605325823700_B9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/rcm.6823","article-title":"Ultra-performance liquid chromatography\/tandem mass spectrometry for determination of sulfatides in dried blood spots from patients with metachromatic leukodystrophy","volume":"28","author":"Han","year":"2014","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2020022605325823700_B10","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"2020022605325823700_B11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1006\/abio.1999.4002","article-title":"Determination of urinary sulfatides and other lipids by combination of reversed-phase and thin-layer chromatographies","volume":"311","author":"Bern\u00e1","year":"1999","journal-title":"Anal Biochem"},{"key":"2020022605325823700_B12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2009.01.011","article-title":"Falsely elevated urinary Gb3 (globotriaosylceramide, CTH, GL3)","volume":"97","author":"Forni","year":"2009","journal-title":"Mol Genet Metab"},{"key":"2020022605325823700_B13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymgme.2009.04.006","article-title":"Gb3\/creatinine biomarkers for Fabry disease: issues to consider","volume":"97","author":"Auray-Blais","year":"2009","journal-title":"Mol Genet Metab"},{"key":"2020022605325823700_B14","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0022-2275(20)32394-4","article-title":"Enhancement of hydrolytic activity of sphingolipid ceramide N-deacylase in the aqueous-organic biphasic system","volume":"41","author":"Kurita","year":"2000","journal-title":"J Lipid Res"},{"key":"2020022605325823700_B15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1373\/clinchem.2012.189936","article-title":"High-throughput assay of 9 lysosomal enzymes for newborn screening","volume":"59","author":"Spacil","year":"2013","journal-title":"Clin Chem"},{"key":"2020022605325823700_B16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10545-015-9822-z","article-title":"Measurement of psychosine in dried blood spots: a possible improvement to newborn screening programs for Krabbe disease","volume":"38","author":"Turgeon","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"2020022605325823700_B17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cca.2013.01.017","article-title":"Determination of psychosine concentration in dried blood spots from newborns that were identified via newborn screening to be at risk for Krabbe disease","volume":"419","author":"Chuang","year":"2013","journal-title":"Clin Chim Acta"},{"key":"2020022605325823700_B18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13361-014-1060-3","article-title":"Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers","volume":"26","author":"Boutin","year":"2015","journal-title":"J Am Soc Mass Spectrom"},{"key":"2020022605325823700_B19","doi-asserted-by":"crossref","first-page":"e7932","DOI":"10.1371\/journal.pone.0079732","article-title":"Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients","volume":"8","author":"Rolfs","year":"2013","journal-title":"PLOS One"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/62\/1\/279\/32644062\/clinchem0279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/62\/1\/279\/32644062\/clinchem0279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T03:31:05Z","timestamp":1653967865000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/62\/1\/279\/5611813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,1]]},"published-print":{"date-parts":[[2016,1,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2015.245159","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,1,1]]},"published":{"date-parts":[[2016,1,1]]}}}